AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON November 25, 1997 REGISTRATION STATEMENT NO. 333-23037

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM SB-2/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

SIGA PHARMACEUTICALS, INC. (NAME OF SMALL BUSINESS ISSUER IN ITS CHARTER)

DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION)

2834 (PRIMARY STANDARD INDUSTRIAL CLASSIFICATION CODE NUMBER)

13-3864870 (I.R.S. EMPLOYER IDENTIFICATION NO.)

666 THIRD AVENUE NEW YORK, NY 10017

-----

(212) 681-4970 (ADDRESS AND TELEPHONE NUMBER OF PRINCIPAL EXECUTIVE OFFICES AND PRINCIPAL PLACE OF BUSINESS) -----

DAVID H. DE WEESE, PRESIDENT AND CHIEF EXECUTIVE OFFICER SIGA PHARMACEUTICALS, INC. 666 THIRD AVENUE

NEW YORK, NY 10017 (212) 681-4970

(NAME, ADDRESS AND TELEPHONE NUMBER OF AGENT FOR SERVICE)

COPIES TO:

ADAM EILENBERG, ESQ. EHRENREICH, EILENBERG, KRAUSE & ZIVIAN SQUADRON, ELLENOFF, PLESENT 11 EAST 44TH ST NEW YORK, NY 10017 (212) 986-9700

FACSIMILE (212) 986-2399

KENNETH KOCH, ESQ. & SHEINFELD, LLP 551 FIFTH AVENUE NEW YORK, NY 10176 (212) 476-8362 FACSIMILE (212) 697-6686

APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC: As soon as practicable after this Registration Statement becomes effective. If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box: [ ]

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of earlier effective registration statement for the same offering. [\_]

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [\_]

If delivery of the prospectus is expected to be made pursuant to Rule 434, please check the following box. [\_]

## SIGNATURES

IN ACCORDANCE WITH THE REQUIREMENTS OF THE SECURITIES ACT OF 1933, THE UNDERSIGNED REGISTRANT CERTIFIES THAT IT HAS REASONABLE GROUNDS TO BELIEVE THAT IT MEETS ALL OF THE REQUIREMENTS FOR FILING ON FORM SB-2 AND AUTHORIZED THIS REGISTRATION STATEMENT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED, THEREUNTO DULY AUTHORIZED, IN THE CITY OF NEW YORK, ON THE 14TH DAY OF NOVEMBER, 1997.

SIGA Pharmaceuticals, Inc.

/s/ David H. de Weese

IN ACCORDANCE WITH THE REQUIREMENTS OF THE SECURITIES ACT OF 1933, THIS REGISTRATION STATEMENT OR AMENDMENT HAS BEEN SIGNED BELOW BY THE FOLLOWING PERSONS IN THE CAPACITIES AND ON THE DATES INDICATED:

SIGNATURE 	TITLE 	DATE 
/s/ Joshua D. Schein Dr. Joshua D. Schein	Chief Financial Officer (Principal Accounting and Financial Officer), Executive Vice President, Secretary and Director	November 25, 1997
/s/ Judson A. Cooper Judson A. Cooper	Executive Vice President and - Director	November 25, 1997
/s/ Terence E. Downer Terence E. Downer	Director -	November 25, 1997
/s/ Donald S. Howard Donald S. Howard	Director -	November 25, 1997

## INDEX TO EXHIBITS

EXHIBIT NUMBER		PAGE
10(0)	Collaborative Research and License Agreement between the Company and American Home Products Corporation, dated as of July 1, 1997*	
11(a) 24(b) 27	Statement re: Computation of per share earnings* Consent of Price Waterhouse LLP* Financial Data Scehdule	

\* Previously filed.

II-2

THIS SCHEDULE CONTAINS FINANCIAL INFORMATION EXTRACTED FROM THE FINANCIAL STATEMENT AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.

